Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness.
In breast cancers, clinical symptoms of inflammation localised around the tumour at the time of diagnosis have been considered to have poor prognosis significance. In this study, the biological mechanisms responsible for the deleterious action of monocytes in cancer were investigated. The incubation of the breast-cancer-derived MDA-MB231 cells with monocytes resulted in an increase in factors involved in cell invasion (i.e. both cancer cells and monocytes-associated urokinase and Tissue Factor, and PAI-1 and MMP-9 secretion). Moreover, the functions of monocytes were also modified. Incubation of monocytes with MDA-MB231 cancer cells resulted in a downregulation in the secretion of the antiproliferative cytokine Oncostatin M, while the apoptotic factor TNF alpha was dramatically increased. However, MDA-MB231 cancer cells have been shown to be resistant towards the apoptotic action of TNF alpha. These findings demonstrate that incubation of MDA-MB231 cancer cells with monocytes induced a crosstalk, which resulted in an increased expression of factors involved in cancer cell invasiveness and in a modification of monocytes function against cancer cells, while inflammatory effects were increased.
Blot
E
E
DIFEMA Laboratory, Medicine and Pharmacy Faculty, Cedex, France. eblot@rouen.fnclcc.fr
Chen
W
W
Vasse
M
M
Paysant
J
J
Denoyelle
C
C
Pillé
J-Y
JY
Vincent
L
L
Vannier
J-P
JP
Soria
J
J
Soria
C
C
D001943:Breast Neoplasms / Q000473:pathology / Q000503:physiopathology*; D045744:Cell Line, Tumor; D018920:Coculture Techniques; D005260:Female; D006801:Humans; D020782:Matrix Metalloproteinases / Q000097:blood / Q000378:metabolism; D009000:Monocytes / Q000166:cytology / Q000502:physiology*; D053683:Oncostatin M; D010455:Peptides / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000378:metabolism; D055293:Receptors, Urokinase Plasminogen Activator; D012016:Reference Values; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
C508351:OSM protein, human; C524898:PLAUR protein, human; D010455:Peptides; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D014409:Tumor Necrosis Factor-alpha; D053683:Oncostatin M; D014568:Urokinase-Type Plasminogen Activator; D020782:Matrix Metalloproteinases